LeadIQ logo
Learn more at LeadIQ.com
✕

Access Insights for Monte Rosa Therapeutics and Millions of Other Companies

Sign up for full access to Monte Rosa Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Insights

Unique Molecular Glue Degrader Medicines Monte Rosa Therapeutics is developing highly selective molecular glue degrader (MGD) medicines for oncology, autoimmune, and inflammatory diseases. This innovative approach presents a unique solution in the pharmaceutical landscape, opening up opportunities to position the company as a pioneer in the field and potentially collaborate with healthcare providers seeking advanced treatment options.

Industry-Leading MGD Pipeline With the industry's leading pipeline of MGDs, Monte Rosa Therapeutics has a strong competitive advantage. This extensive pipeline not only showcases the company's commitment to innovation but also provides a wide range of product offerings, presenting ample opportunities to engage with pharmaceutical distributors and expand market reach through strategic partnerships.

Strategic Expansion and Leadership Development Monte Rosa Therapeutics recent expansions and leadership promotions, including appointing new key officers, indicate strategic growth and a focus on talent development. This presents an opportunity for partnership discussions with institutions looking to collaborate with a forward-thinking company poised for continued success in the biotechnology sector.

Funding and Financial Stability Having secured substantial funding and with a revenue range of $10M - 50M, Monte Rosa Therapeutics demonstrates financial stability and growth potential. This financial health not only enhances the company's credibility but also attracts potential investors and partners interested in aligning with a financially sound organization for mutual beneficial sales opportunities.

Differentiated Target Space and AI-Driven Discovery Monte Rosa's QuEEN™ discovery engine offers access to a differentiated target space through AI-guided chemistry and innovative proteomics approaches. This technological sophistication presents a compelling narrative for engagement with technology partners seeking to leverage advanced scientific methodologies and collaborate with a company at the forefront of biotechnological innovation.

Similar companies to Monte Rosa Therapeutics

✕

Access Insights for Monte Rosa Therapeutics and Millions of Other Companies

Sign up for full access to Monte Rosa Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Monte Rosa Therapeutics Tech Stack

Monte Rosa Therapeutics uses 8 technology products and services including Microsoft PowerPoint, ADP, Exhibit, and more. Explore Monte Rosa Therapeutics's tech stack below.

  • Microsoft PowerPoint
    Editors
  • ADP
    Human Resource Management System
  • Exhibit
    Javascript Graphics
  • Open Graph
    Miscellaneous
  • PHP
    Programming Languages
  • Python
    Programming Languages
  • C#
    Programming Languages
  • VMware
    Virtualisation Software

Media & News

Monte Rosa Therapeutics's Email Address Formats

Monte Rosa Therapeutics uses at least 1 format(s):
Monte Rosa Therapeutics Email FormatsExamplePercentage
FLast@monterosatx.comJDoe@monterosatx.com
98%
FMiddleLast@monterosatx.comJMichaelDoe@monterosatx.com
1%
LF@monterosatx.comDJ@monterosatx.com
1%

Frequently Asked Questions

Where is Monte Rosa Therapeutics's headquarters located?

Minus sign iconPlus sign iconMonte Rosa Therapeutics's main headquarters is located at 321 Harrison Ave Suite 900 Boston, Massachusetts 02118 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Monte Rosa Therapeutics's stock symbol?

Minus sign iconPlus sign iconMonte Rosa Therapeutics is a publicly traded company; the company's stock symbol is GLUE.

What is Monte Rosa Therapeutics's official website and social media links?

Minus sign iconPlus sign iconMonte Rosa Therapeutics's official website is monterosatx.com and has social profiles on LinkedIn.

How much revenue does Monte Rosa Therapeutics generate?

Minus sign iconPlus sign icon As of October 2024, Monte Rosa Therapeutics's annual revenue reached $15M.

What is Monte Rosa Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign iconMonte Rosa Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Monte Rosa Therapeutics have currently?

Minus sign iconPlus sign iconAs of October 2024, Monte Rosa Therapeutics has approximately 163 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: M. W.Chief Information Officer: J. C.Chief Medical Officer: F. J.. Explore Monte Rosa Therapeutics's employee directory with LeadIQ.

What industry does Monte Rosa Therapeutics belong to?

Minus sign iconPlus sign iconMonte Rosa Therapeutics operates in the Biotechnology Research industry.

What technology does Monte Rosa Therapeutics use?

Minus sign iconPlus sign iconMonte Rosa Therapeutics's tech stack includes Microsoft PowerPointADPExhibitOpen GraphPHPPythonC#VMware.

What is Monte Rosa Therapeutics's email format?

Minus sign iconPlus sign iconMonte Rosa Therapeutics's email format typically follows the pattern of . Find more Monte Rosa Therapeutics email formats with LeadIQ.

How much funding has Monte Rosa Therapeutics raised to date?

Minus sign iconPlus sign icon As of October 2024, Monte Rosa Therapeutics has raised $100M in funding. The last funding round occurred on May 16, 2024 for $100M.
Monte Rosa Therapeutics

Monte Rosa Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.

✕

Access Insights for Monte Rosa Therapeutics and Millions of Other Companies

Sign up for full access to Monte Rosa Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Section iconCompany Overview

Headquarters
321 Harrison Ave Suite 900 Boston, Massachusetts 02118 US
Website
monterosatx.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
GLUE
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $100M

    Monte Rosa Therapeutics has raised a total of $100M of funding over 5 rounds. Their latest funding round was raised on May 16, 2024 in the amount of $100M.

  • $10M$50M

    Monte Rosa Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $100M

    Monte Rosa Therapeutics has raised a total of $100M of funding over 5 rounds. Their latest funding round was raised on May 16, 2024 in the amount of $100M.

  • $10M$50M

    Monte Rosa Therapeutics's revenue is in the range of $10M$50M

Company Leadership

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

✕

Access Insights for Monte Rosa Therapeutics and Millions of Other Companies

Sign up for full access to Monte Rosa Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.